Company intelligence / Profile preview

Farapulse

Menlo Park, California, United Statesfarapulse.com ↗

Ownership: Private
Development stage: Commercial

Overview

The FARAPULSE PFA system has demonstrated safety and efficacy comparable to conventional thermal ablation methods in large pivotal trials. Real-world registry data from over 17,000 patients confirm a favorable safety profile with low rates of major complications. FDA approval was granted in early 2024 for paroxysmal AF; ongoing studies are evaluating broader uses including persistent AF and as a first-line therapy. Over $1 billion revenue was generated by Boston Scientific from this product in its first year post-FDA approval.

Therapeutic areas: OtherCardiovascular
Modalities: DeviceNon-pharmacological therapy (Pulsed Field Ablation system)
Industry: Therapeutic Medical Devices

Partnerships

Early investment/partnership with F‑Prime CapitalCollaboration with Boston Scientific pre-acquisition

Beyond the preview

Go deeper on Farapulse.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Farapulse.

Explore the full profile